TRIPLE-1-INC.
4.2.2020 12:02:06 CET | Business Wire | Press release
TRIPLE-1 Inc. (Headquarters: Hakata-ku, Fukuoka-shi, Fukuoka; Representative Director CEO: Takuya Yamaguchi; Henceforth: TRIPLE-1) has announced two new products: The ASIC "KAMIKAZE Ⅱ" for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005385/en/
--- Overview
In the "cryptocurrency mining market" that is driving the miniaturization of semiconductor processes in recent years, an extremely severe business model has been formed that directly links the power performance of semiconductors used for mining with mining proceeds. Starting in February 2017, TRIPLE-1 has been using core know-how involving the designability for cutting edge processes, the optimization of electrical consumption, and the improvement of the yield rate that have been fostered from the development of ASIC (application-specific integrated circuits) for cryptocurrency mining. Development has started on both "KAMIKAZE Ⅱ", the latest high-performance ASIC for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.
--- Next generation 7 nm Bitcoin mining ASIC "KAMIKAZE Ⅱ" – That design completed
By making use of the know-how fostered from the initial "KAMIKAZE" model, the design for the next generation model "KAMIKAZE Ⅱ" has been finalized. After tape outing to TSMC and the prototype has been inspected, we will start mass production from 2021.
Additionally, we have started to offer reference boards and reference designs for the first "KAMIKAZE" mining machine model, the system that can provide smoother installation support is ready.
< Feature > ASIC Boost is built-in, improving the mining efficiency rapidly
By loading the custom algorithm "ASIC Boost" that improves mining efficiency (it was not loaded on to the first “KAMIKAZE” model), a more highly efficient mining environment is provided. Additionally, by supporting ultra-low voltage drive (supplied voltage 0.2x V), we anticipate a drastic reduction in electrical consumption.
KAMIKAZE / KAMIKAZE Ⅱ Performance specifications comparison
|
KAMIKAZE |
KAMIKAZE Ⅱ |
Process |
TSMC 7 nm |
TSMC 7 nm improved process |
Die size |
3.5 × 3.9 mm |
3.0 × 9.0 mm |
Package |
7 × 7 mm FC-BGA |
7 × 12 mm FC-LGA |
Input voltage |
0.3 V or less |
Drives at a lower voltage than KAMIKAZE |
Power consumption |
1.2 W / chip |
6.7 W / chip |
Hash rate |
23 GHs / chip |
240 GHs / chip |
Electrical efficiency |
52 W / THs |
28 W / THs |
ASIC Boost |
None |
Supported |
*KAMIKAZE: Chip actual value, KAMIKAZEⅡ: Design target
--- New challenges, enter the AI market
In recent years, various companies have entered the AI chip market, including not only giant IT companies but also fast-growing start-ups in China. As competition for edge AI chip development intensifies, oligopoly supply by several major companies continues in the deep learning AI processor market. Currently there are no mass-produced chips smaller than 12 nm process.
On the other hand, the electrical consumption of data centers is expected to excess 10% of the entire world's electrical energy by 2030. TRIPLE-1 believe that AI processors for deep learning need not only high "computing power" to learn and process a huge amount of data, but also a severe viewpoint on "power consumption" from the viewpoint of energy conservation and cost reduction.
Therefore TRIPLE-1 has launched the project to develop "GOKU", an ultra-low power consumption dedicated deep learning AI processor using the world's most advanced 5nm process, utilizing our unique Low power / High performance technology and design know-how in the most advanced processes.
--- "GOKU", an AI processor for deep learning with the world's leading 5 nm process
The first stage prototype has been completed, and we are inspecting the performance. Realizing the mass production in 2021, we will complete the prototypes closer to mass-produced products within 2020. It will be sold to the equipment and devices manufacturers for data servers or deep learning centers around the world, and we have already begun to discuss with multiple companies.
< Feature > Using the world's leading 5 nm process, it has 10 times higher power efficiency than conventional
Our goal is to reduce power consumption by 1/10 of the equivalent performance compared to conventional products (process: 12 nm), and its feature is low-voltage operation that is inconceivable with existing products.
< Feature > Design to connect multiple calculation units
Like the structure of the human brain, where synapses connect neurons in a complex manner, great amount and very complex inter-core communication is important for deep learning AI processors.
Utilizing the unique circuit design technology of "GOKU", which arranges many small arithmetic units on one large die as much as possible, it is designed to secure the communication (interconnect) band between the arithmetic units as much as possible.
It has been designed to get closer to the human brain.
< Reference > GOKU performance table (Design target)
Process |
5 nm |
Power consumption |
100 W |
Peak performance (half-precision) |
1 PFLOPS (1,000 TFLOPS) |
Electrical efficiency (half-precision) |
10 TFLOPS / W |
--- TRIPLE-1 outline
Company Name: TRIPLE-1, Inc.
Corporate Headquarter:
7F IT Bldg.Ⅱ,1-14-20 Hakataeki-Higashi, Hakata-ku Fukuoka-shi, Fukuoka, Japan
Representatives: Representative Director CEO Takuya Yamaguchi
The capital: 3662 million 895 thousand and 398 yen (including the capital reserve)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005385/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
